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Aims: In India, larger proportions of patients with ACS present with STEMI. We sought to
study the recent trends of reperfusion in patients of acute STEMI.
Methods and Results: 1905 patients presenting with acute STEMI enrolled. 1636 (86%) received
some form of reperfusion therapy. Streptokinase, 1235 (65%) patients, was the most
common mode of reperfusion therapy used followed by primary PCI (205, 10.7%) and ten-
ecteplase (196, 10%). 269 (14%) did not receive any form of reperfusion therapy, the most
common reason being late presentation in 230 (85.7%). Patients presenting with STEMI
increased from 297 to 446 comparing first and last half-year of study period. The PCI and
tenecteplase numbers increased from 19 to 68 and 27 to 97 respectively.
Conclusion: There was 20% increase in STEMI every year. Younger patients are least likely to
receive primary PCI or tenecteplase. 1 in 8 patients of STEMI did not receive any form of
reperfusion therapy.
Copyright ª 2012, Cardiological Society of India. All rights reserved.1. Introduction requires specific and relevant data applicable to the generalCoronary artery disease (CAD) is the most common cause of
death in both developing and developed countries.1 By 2020
CAD is expected to increase by more than 120% in the devel-
oping countries as compared to 30e40% in the developed
countries.2 60% of the world’s heart disease is expected to
occur in India.3 This will place a huge strain on healthcare
resources which are already inadequate and overstretched.
Providing optimal care to patients of CAD in the Indian setting.
om (B.K. Kunwar).
2012, Cardiological Sociepopulation.
The spectrumof CAD in the developed countries appears to
be different from that in the Indian population. Less than 40%
of the patients with acute coronary syndrome present with
ST-Segment Elevation Myocardial Infarction (STEMI) in the
developed countries4,5 and this is also showing a decreasing
trend with time. On the other hand 60% of patients with ACS
present with ST segment elevation myocardial infarction in
India. In patients with ST elevation myocardial infarction, thety of India. All rights reserved.
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influenced by duration from onset of symptoms. The best
treatment for patients presenting with STEMI is reperfusion
either in the form of primary Percutaneous coronary inter-
vention (PCI) or by means of thrombolytic agents. Primary PCI
re-establishes blood flow in the culprit coronary artery by
mechanically dislodging the thrombus obstructing the vessel
and has been shown consistently in most studies to be supe-
rior to thrombolytics. Primary PCI is not available in most
tertiary care centres in India. So in most centres treatment of
STEMI is based on pharmacological thrombolysis by using
streptokinase or tenecteplase.
Most data on patients with acute coronary syndromes are
derived from several large registries from developed
countries.6e13 Data regarding revascularization in STEMI from
India came from study by Jose and Gupta (2004) and CREATE
study.15 The study by Jose et al was a single-centre study done
in pre PCI era of CMC Vellore. It enrolled 1320 patients with
STEMI with mean age of 56  13. Males comprised of 83.6% of
patients and 82.8% of patients underwent reperfusion only by
means of thrombolytic. CREATE registry which was
a prospective registry done in 89 centres from 10 regions and
50 cities in India. It enrolled 20,937 patients out of which
12,405 (60.6%) had STEMI. The mean age of these patients was
57.5 (SD 12.1) years. 6226 (30.4%) patients had diabetes; 7720
(37.7%) had hypertension; and 8242 (40.2%) were smokers.
Percutaneous coronary interventions were used in 8% in
STEMI. Thrombolytic (96.3% streptokinase) were used for
58.5% of patients with STEMI.
We present data from a registry of 1905 patients with
STEMI who presented to CMC Vellore looking at the treatment
modalities used for reperfusion.
In this study, we aim to study the current trends in
revascularization in STEMI in a tertiary care centre in South
India.We also assessed the number and proportion of patients
receiving pharmacological or invasive reperfusion treatment
of STEMI. The number of patients not receiving any form of
reperfusion therapy and the reasons for the same were also
evaluated.2. Materials and methods
This was a retrospective observational study done in Vellore,
which is a tier 3 South Indian city. It is a single-centre study
done in the Cardiology department of Christian Medical
College, a tertiary care centre. The Department of Cardiology
CMC Vellore is equipped with all the required facilities for
tackling cardiac emergencies and primary PCI. The cardiac
catheterization laboratory was established almost 45 years
back. The cardiac catheterization laboratory and interven-
tional cardiologists are available round the clock. The
department caters around 700e800 patients of acute ST
elevation myocardial infarction per year.
2.1. Subjects
All patients irrespective of age who presented with acute
STEMI were included in the study. Patients coming with
STEMI are usually local with poor socioeconomic status.Affordability of interventional procedures is always
a problem. As Vellore district covers a large rural population,
awareness among people about coronary artery disease and
the recent advances in treatment are deficient.
2.2. Data collection and analysis
The number of patients thrombolysed with streptokinase,
tenecteplase or undergoing primary PCI was determined.
Their percentages, mean and standard deviations were
calculated. The data was scrutinized for the trends in revas-
cularization. Data were collected from the in-patient and out-
patient records as well as the records in the Coronary Care
Unit (CCU)/Chest Pain Unit (CPU). Patients were divided into
age groups of 20e39, 40e59, 60e79 and >80 years. Other
variables that were taken into account included age, gender
and risk factors for coronary artery disease. The number of
patients not revascularized and the reasons for the samewere
also studied. Sample size was calculated using the formula
4PQ/D2, using data from CREATE study. P is percentage of
patient revascularized in the previous study. Q is 100P.3. Results
Between 1st August 2008 and 28th Feb 2011, a total of 1905
patients with ST-segment elevation myocardial infarction
(STEMI) were enrolled into this study. The demographic
characteristics of the patients are presented in Tables 1 and 2.
The largest number of patients was in the age group of 40e59
years (949, 49.8%). Younger age group included 153 (8%)
patients. 49 (2.6%) patients were >80 years. 1636 (86%) of
patients received some form of reperfusion therapy either by
thrombolytic agent or PCI. Thrombolytic with streptokinase
was the most common mode of reperfusion. 1235 (75.5%) of
the total STEMI patients were reperfused with it. It was also
the most common mode of reperfusion in all age group
categories.
This was followed by primary PCI which was used in total
of 205 patients (11%). The age group in which this modality
was most utilized was 40e59 years (103, 50%). Patients with
age >80 years were least benefited by PCI (2.4%) followed by
age group 20e39 years (10.2%). Tenecteplase was used in 196
(10%) patients. 269 (14%) did not receive any form of reperfu-
sion for various reasons. The most common reason for not
receiving reperfusion therapy was late presentation in 230
(85.5%) patients followed by cardiogenic shock or death in 32
(12%) (Fig. 1). There were 7 patients who were denied throm-
bolytic agents because of contraindications for thrombolysis.
Out of which 5 patients had either recent or associated cere-
brovascular accident and 2 had an associated pericardial
effusion.
Mean age of patients in the whole study population was
56.3þ 11.8 years. Maximumpatients were in the age groups of
40e59 years with least in >80 years.
Patients with STEMI increased progressively in every 6
months assessment. It was 297 patients to start with in 1st
half-year which became 465 and 446 in the last two half-years.
Number of patients utilizing STK as thrombolytic agent
remained same in first half-year and the last half-year (Fig. 4),
Table 1 e Demographic characteristics of patients.
STK lysis (%) TNK lysis (%) Primary PCI (%) Nil (%) Total (%)
Total 1235 (65) 196 (10) 205 (10.7) 269 (14) 1905
Age 20e39 114 (9.2) 8 (4) 21 (10.0) 11 (4) 153 (8)
Age 40e59 627 (50.7) 88 (44.9) 103 (50) 123 (45.7) 949 (49.8)
Age 60e79 468 (37.9) 96 (49) 76 (37) 116 (43) 754 (39.5)
Age >80 26 (2.1) 4 (2) 5 (2.4) 19 (7.6) 49 (2.6)
Age mean þ SD 58.8 þ 13 61 þ 9.4 55.6 þ 12 58 þ 12 56.3 þ 11.8
Male 1024 (83) 172 (88) 184 (90) 197 (73) 1577 (83)
Female 211 (17) 24 (12) 21 (10) 72 (27) 328 (17)
AWMI 719 (58) 117 (59) 125 (61) 189 (70) 1150 (60)
IMI 497 (40) 76 (39) 79 (38.5) 75 (28) 727 (38)
Others 19 (2) 3 (1.5) 1 (0.5) 5 (1.8) 28 (1.5)
DM 617 (50) 94 (48) 110 (54) 123 (46.6) 944 (49.5)
HTN 407 (32.9) 80 (42) 74 (36) 96 (36.6) 657 (34)
Dyslip 864 (73) 111 (57) 171 (84) 199 (74.4) 1345 (70)
Smoking* 370 (30.7) 82 (42) 70 (34) 67 (25.5) 589 (31)
Data are number (%) or  standard deviation.
IMI includes inferior and all other combinations (right ventricular, posterior and lateral).
AWMI includes anterior, antero-sepal, anterolateral and extensive anterior wall STEMI.
Others include high lateral, isolated lateral or posterior wall STEMI.
Includes both current and ex-smoker (*).
i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 3 6 8e3 7 3370even though the proportion decreased from 75.5% in first half-
year to 48% in last half-year. Patient who did not receive any
form of revascularization too increased from 35 (11.8%) in the
first half-year to 65 (14.6%) in the last half-year. The use of
tenecteplase was almost the same in the first four half-years,
however there was an exponential rise in the last half-year
duration.
In all treatment groups the proportion of males was more
than females. Overall 83% of total STEMI patients were male
and 17%were females. In the group of patients not reperfused,
females were 72 (26.7%), for tenecteplase (24, 12%), PCI (21,
10%) and streptokinase 211 (14.4%).
Most common territory involved was anterior wall which
constituted 1150 (61%) patients. Inferior wall STEMI in various
combinations was 727 (38%). Other territories included highTable 2 e Comparison of baseline characteristics and
management strategy outcomes of patients enrolled in
earlier study by Jose et al14 from the same centre vs
present study.
Characteristics Earlier study Present study
N ¼ 1320 (%) N ¼ 1905 (%)
Age 56  13 56.3  11.8
Males 1106 (83.8) 1577 (83)
Females 214 (16.2) 328 (17)
Smoking 569 (43.1) 589 (31)
Diabetes mellitus 531 (40.2) 944 (49.5)
Hypertension 504 (38.2) 657 (34)
Location of MI
Anterior wall MI 752 (57) 1150 (60)
Inferior wall MI 517 (39) 727 (38)
Reperfusion therapy
STK 1093 (82.8) 1235 (65)
TNK Nil (0) 196 (10)
PCI Nil (0) 205 (10.7)lateral, isolated posterior wall etc were 28 (1.%). 49.7% of the
patients has type 2 diabetes mellitus. 73% of patients had
dyslipidemia. 34% of the patients had hypertension. 31% of
the patients were either current or ex-smoker. 60% of the
patients have at least 2 risk factors.4. Discussion
Mean age of presentation of STEMI in present study was
56.3  11.8 years with majority of them being males (83%). In
the study done by Jose and Gupta (2004), which included
patients from 1999 to 2003 in the same centre and the
CREATE15 registry which enrolled patients from 2001 to 2005,
the mean age been 56  13 years and 57.5  12 years. This is
suggesting that mean age of patients has not change over
a decade even when comparing data from the same centre.250
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Fig. 1 e Reasons for not utilizing reperfusion therapy.
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Fig. 4 e Changes in lysis strategy over study period.
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Fig. 2 e Age distribution for reperfusion therapy.
i n d i a n h e a r t j o u rn a l 6 4 ( 2 0 1 2 ) 3 6 8e3 7 3 371Patients enrolled in this study presented a decade earlier in
comparison to the western data where the mean age of
presentation has increased from 64.1 years to 66.4 years. Early
age of STEMI could lead to tremendous loss of productive
years and can have an adverse outcome on the economy as
well as national health.
It is noteworthy that only a small percentage of patients in
younger age group of 20e39 years received PCI (10.7%) and
tenecteplase (4%) as compared to the 40e59 years age group
(PCI 50%, tenecteplase 44.9%). This relates to the social status
and financial means of the patients enrolled in the study.
Younger patients whowould be benefited themost in terms of
productive life-years saved remain the least benefited by
recent advances in reperfusion therapy.
In the present study, women comprised 17% of all patients,
whichwas comparable to the proportion of women patients in
the CREATE study (18%) and the study by Jose et al (16.2%). The
data also highlighted the inferior treatment received by
women in comparison tomen, as of the patients who received
PCI only 10% were women. Similarly, women comprised only
12% of all STEMI patients who received tenecteplase as
a thrombolytic agent.4.1. Trends in STEMI
There was steady increase in admissions of patients with
STEMI over a period of 2½ years which was divided into five
half-years for analysis. There was almost 20% increase in the
number of STEMI, if we compare the first two half-years with500
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Fig. 3 e Trends of reperfusion in STEMI. *Numbers
represent months in serial order from July 08 to Feb 11.the last two (Fig. 3). This increment raises serious concern that
the incidence of STEMI is likely to be doubled in less than 4
years in the local population. There was increase of approxi-
mately 30% of STEMI patients from the first half-year to the
last two. In the first half-year, streptokinase was used in 72%
of patients of all STEMI. This percentage remained almost the
same till the first four half-years; however in the last half-year
only 48.4% of STEMI patient’s utilized streptokinase. So even
though the numbers of patients of STEMI have increased, the
role of streptokinase as the main thrombolytic agent
remained the same over the first 2 years period of study, but
newer modalities in the form of PCI and TNK together
constituted 37% of STEMI patients in the last half-year
reflecting a very significant change in reperfusion strategy.
Streptokinase constituted 86% of all thrombolysed cases. This
is in comparison to data from CREATE study in which
thrombolytic (96% streptokinase) were used for 58.5% of
patients with STEMI and study of Jose and Gupta, 2004 in
which 82.8% of patients received thrombolytic (all with
streptokinase).
A very important result of this study was the analysis of
patients who did not receive any reperfusion therapy because
of various reasons. 14% patients of STEMI did not receive
reperfusion therapy over the period of two and a half-years;
there was 46% increase in the number of such patients
between the 1st and the last half-years, which is very alarm-
ing considering that this number should ideally be expected to
fall. In comparison, in the study by Jose andGupta (2004) 17.2%
patient did not receive reperfusion therapy. So even a decade
after the study by Jose and Gupta, 2004, the reperfusion
therapy usage in STEMI has only marginally increased. The
most important reasons for no reperfusion therapy usage was
late presentation (85.5%) (Fig. 2). There were many reasons for
this, such as late diagnosis and referral, poor transport facil-
ities and lack of awareness in the general population. Even
though, females formed only 17% of all STEMI patients, they
constituted 27% of patients not receiving reperfusion therapy
(Fig. 5). So reperfusion therapy usage rates were lower in
female patients as compared to males.
Cardiogenic shock and death prior to instituting reperfu-
sion therapy (12%) was the second most common cause for
not receiving reperfusion therapy. These patients could have
been treated with primary PCI, if they could have afforded it.
High cost of PCI procedures and its non-availability even in
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Fig. 5 e Gender percentage for reperfusion strategy.
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drawbacks in the management of STEMI in India.
There were 7 patients who had an absolute contraindica-
tion to thrombolytic therapy. Five of them had a recent cere-
brovascular accident and one had a concurrent large
ischaemic stroke. Two patients were not offered thrombolytic
in view of large associated pericardial effusion. PCI would
have been the best option in these patients, if they could have
afforded it. Tenecteplase was used in 10% of patients, where
as in the study by Jose et al study the only thrombolytic used
was streptokinase. The number of patients who were throm-
bolysed with tenecteplase remained almost same till the first
four half-years studied following which it has an exponential
rise in last half-year. Tenecteplase was used in 9% of all STEMI
patients in the first half-year compared to only 21.7% in the
last (Fig. 4). The cost of tenecteplase still was the reason for
fewer patients being thrombolysed with it. The cost of ten-
ecteplase in our centre is 7e8 times that of streptokinase.
Interestingly, it was found thatmost of the patients who could
afford tenecteplase, could afford PCI as well and so opted for
the latter. So even though TNK is replacing STK as thrombo-
lytic agent in our centre, to do it completely, its price has to
come down significantly.
Primary PCI was used in 10.7% of patients as a reperfusion
modality. Therewas 20% increase in primary PCI between first
and 2nd year of study. In the 1st half-year PCI was used only in
6.3% of all STEMI patients and this percentage increased to
15.2% in the last half-year. So even though the percentage of
primary PCI between 1st and the last half-year has almost
doubled, this may not be adequate considering 30e35%
increase in the rates of STEMI hospitalizations during this
period.
This study also analyzed the main risk factors for CAD
prevalent in the Indian population. Diabetes mellitus was
found in 49.7% of patients; systemic hypertension was found
in 34; 31% of patients were either current or ex-smokers and
73% of patients had some form of dyslipidemia. This data is
different from data from CREATE study where 34% patients
had diabetes; 37.7% had hypertension; and 40.2% were
smokers. Study from Jose et al from the same centre as the
present study a decade back showed 40.2% prevalence of
diabetes in STEMI patients. So data from present study
demonstrates an increase in the proportion of patients with
diabetes as compared to the past studies and suggest a strong
correlation of diabetes mellitus with coronary artery disease.There may be other non-conventional risk factors for e.g.
Mediterranean diet, stress, depression, playing an important
role in pathogenesis of coronary artery disease (Singh et al,
2010; Tee and Hassan, 2011; Corona et al, 2011). These factors
may play an important role in young patients especially those
who lack conventional risk factors.
There were many differences between the present study
and the study by Jose and Gupta (2004) and the CREATE
registry. The study by Jose and Gupta (2004) was done
a decade ago in the same centre as the present study.
Thrombolytic with streptokinase was the only mode of
reperfusion in patients of STEMI, where as in the present
study STK is considered as a last option for reperfusion
therapy after PCI and tenecteplase. Data on gender and
territory of MI has remained almost the same in the two
studies. Prevalence of diabetes mellitus has increased 10%
in STEMI patients over a decade which may be the reason
for increased number of patients presenting with STEMI in
the present study. The present study differed from the
CREATE registry as it is a single-centre study as compared to
the multi-centre CREATE registry.
The present study highlights the current scenario of STEMI
and its management in a tier 3 South Indian city. Even with
a tertiary care centre with cardiac catheterization laboratories
and experienced cardiologists available 24 h a day, the rates of
primary PCI have been low. Many reasons are responsible for
this. Themost important being the financial constraints of the
patients; most patients in India pay for emergency medical
expenses themselves and lack insurance cover. Tenecteplase
is in process of replacing STK as a main thrombolytic agent
but it has a long way to go.
Lack of awareness in general population and poor referral
and transport have an important role to play. Increasing the
numbers of tertiary cardiac centres alone is unlikely to be
sufficient to improve the management of STEMI; the efforts
have to be made in all directions.5. Conclusion
Patients with STEMI in this study are decade younger than
western population. There was 20% increase in STEMI every
year in the studied population. The younger patients are least
likely to get primary PCI or tenecteplase as reperfusion
therapy. 86% of patients received some form of reperfusion
therapy in this study. Streptokinase was the most common
type of reperfusion therapy used. Primary PCI rates showed
increasing trend but still only 10% STEMI patients receive it.
Use of tenecteplase, which is a better replacement for
streptokinase showed exponential rise in the last half-year
but much more needs to be done especially in terms of cost
reduction so that it can completely replace streptokinase in
centres where PCI is not available. In present study, 1 in 8
patients of STEMI didn’t receive any form of reperfusion
therapy. Most common reason for this was late presentation.
Almost 50% of STEMI patients had diabetes mellitus signi-
fying the role of diabetes mellitus as a major risk factor for
coronary artery disease in Indian population. Out of all
STEMI, 3/5th of them were involving anterior wall indicating
high risk STEMI.
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